Tumorile neuroendocrine pancreatice (PNET-uri) sunt tumori rare, cu semne clinice variabile şi management chirurgical adesea provocator. Metode: Am efectuat un studiu retrospectiv în Clinica 1 Chirurgie, Spitalul Universitar Sf. Spiridon, în ultimii 17 ani, care a inclus toţi pacienţii diagnosticaţi imunohistochimic cu tumori endocrine pancreatice, 61 tumori endocrine digestive (GINET and PNET). Rezultate: Au fost 26 de cazuri diagnosticate cu PNET. Proporţia bărbaţi / femei a fost de 7/19, iar vârsta medie a fost de 41,93 ± 2,48 ani (între 20 şi 79 de ani). 13 insulinoame, 5 gastrinoame, 2 gastrinoame asociate cu alte neoplazii endocrine (sindrom Wermer), 5 tumori pancreatice non-functionale şi 1 caz de ACTH-oma. Diagnosticul a fost sugerat de triada Whipple, în insulinoame, de sindromul Zollinger Ellison în gastrinoame şi sindrom Cushing în ACTHoame. Diagnosticul biologic a inclus markeri biologici (insulină, gastrină, cortizol). Diagnosticul topografic şi dimensiunii tumorii au fost appreciate prin examen cu ultrasunete, CT-scan, angiografie, PET-scan, Octreoscan şi ultrasonografie intraoperatorie. Procedurile chirurgicale pentru insulinoamele au fost: rezecţia tumorii -6 cazuri; splenopancreatectomii stângi -3 cazuri; pancreatectomii stângi cu conservarea splinei -2 cazuri; duodenopancreatectomii cefalice -2 cazuri. De asemenea, prezentăm 5 cazuri de gastrinom cu ulceraţii multiple şi intervenţii chirurgicale multiple pentru hemoragie şi perforaţie cu peritonită. Cei doi pacienţi cu sindrom Wermer au avut, de asemenea, ulcere Original Article complicate cu hemoragie şi peritonită şi adenom paratiroidian. Am tratat 5 tumori endocrine pancreatice nonfuncţionale situate în coada pancreasului în 3 cazuri (splenopancreatectomie şi pancreatectomie stângă cu conservarea splinei) şi în capul pancreatic în 2 cazuri (duodenopancreatectomie cefalică şi o operaţie tip Beger). Concluzii: Este necesară recunoaşterea semnelor clinice ale tumorilor secretante şi explorarea pacienţilor cu PNET. Imunohistochimia este obligatorie pentru confirmare, aprecierea proliferării şi a comportamentului biologic al tumorii şi permite utilizarea unei terapii specifice. Tratamentul chirurgical agresiv este indicat, chiar şi în stadii avansate.
Introduction
Pancreatic neuroendocrine tumors (PNETs) are part of the gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a heterogeneous group of tumors originating from neuroendocrine cells that can occur throughout the digestive tract (1) .
In 2010 WHO introduced the term neuroendocrine and simplified the classification of these tumors by using histological (number of mitoses/10 HPF) and immunohistochemical criteria (Ki 67 index) (2) .
Most NETs are GEP-NETs -over 90%. Of these, the most common are small bowel NETs (43%), colorectal NETs (27%) and pancreatic NETs (PNETs) -28% (3, 4) . In recent years the overall incidence of PNETs is an increase, probably due to the advances in diagnosis (imaging, immunohistochemistry, genetics, and molecular biology).
Non-functional PNETs represent 15-70% of all neuroendocrine tumors of the pancreas. Insulinoma and gastrinoma are the most common functional PNETs and the sporadic forms are more common than those occurring in MEN syndromes. With the exception of gastrinoma, almost all tumors have a slightly higher incidence in women. PNETs occur in patients aged 30-60 years (3) .
Methods
This retrospective study was done at The First Surgical Unit of the Iaşi "Sf. Spiridon" University hospital between 2001 and 2018. Clinical, laboratory, intraoperative and histopathological data were included in a MS Access Office XP database.
Included in the study were only the patients operated for digestive endocrine tumors diagnosed histopathologically and confirmed immunohistochemically.
A multidisciplinary team evaluated each patient in order to determine the likely origin, malignant vs benign morphological characteristics, and chances for a successful surgical approach.
Results and Discussions
During the study interval 61 patients diagnosed with digestive endocrine tumors have been treated, of which 26 PNETs and 35 GI-NETs (stomach -5 cases, duodenum -1 case, small bowel -10 cases, appendix -9 cases, colorectal -6 cases, liver metastasis -4 cases, of which 3 cases with primary GI-NET tumors operated in another surgical clinic).
Male/female ratio was 19/42 (30%/70%) with no difference between PNET compared to GI-NET. Mean overall age was 41.93 ± 2.48 years (range 20-68 years): mean age in PNET group was 41.90 ± 3.095 years (range 27-68 years) and in GINET group 42 ± 4.365 years (range 20-79 years).
Next we will refer only to PNET. We treated the following PNET types: insulinoma -13 cases, gastrinoma -7 cases, nonfunctional PNET -5 cases, ACTHoma -1 case.
Most cases were recorded in women. Male/ female ratio was: insulinoma -3/10, gastrinoma -2/5, nonfunctional PET -1/4, ACTHoma -0/1. In order of frequency a literature review of the PNETs described so far are: insulinomas (70% of PNETs), gastrinomas (Zollinger-Ellison syndrome, 20%), VIPomas (Verner-Morrison syndrome, 3%), glucagonomas (1%), the other tumors accounting less than 1% (somatostatinoma, ACTHoma, GRFoma, serotoninoma, PPoma, PNET secreting calcitonin, renin, luteinizing hormone, neurotensin, ghrelin, cholecystokinin, erythropoietin, insulin-like growth factor-2) and non-secreting pancreatic endocrine tumors -30% (5) .
Clinical manifestations depended on the tumor type: hypoglycemia and Whipple triad for insulinoma, Zollinger Ellison Syndrome and complicated peptic ulcer (hemorrhage, perforation) for gastrinoma, Cushing syndrome for ACTHoma.
Biological diagnosis included the following biological markers: insulin, gastrin, and cortisol. Tumor site and size were determined by ultrasound, CT-scan, angiography, PET-scan (1 case), octreoscan (1 case). Histopathological and immunohistochemical diagnosis were made in all cases. Tumor sizes were: for insulinoma -2.75 ± 0.21/ 1.5-4 cm, for gastrinoma -1.75 ± 0.75/ 1-2.5 cm, ACTHoma -2.5 cm, nonfunctional PNET -5.12 ± 0.96/ 3-7 cm (ANOVA test; p=0.010). PNETs were predominantly located in the body and tail of the pancreas (Table 1) .
Multiple endocrine neoplasia type 1 (MEN 1) was diagnosed in 4 cases (3 cases associated with gastrinoma and 1 case associated with insulinoma. In another case not included in this series PNET was associated with extraadrenal pheochromocytoma and ovarian cyst.
PNET -insulinoma
PNET -insulinoma is produced by the proliferation of pancreatic beta cells, characterized by insulin hypersecretion independent of the blood glucose regulation system. Diagnosis was made based on: the classic clinical triad known as "Whipple triad" -symptoms and signs of hypoglycemia, blood glucose level below 50 mg/dL (2.7 mmol/L), and relief of symptoms after glucose administration and high insulin levels; ultrasound ( Fig. 1 ) and CT-scan ( Fig. 2, 3 ) were performed in all cases. Various brain injuries due to severe hypoglycemia were recorded in 9 cases. Diagnosis was delayed in 8 cases due to neuropsihiatric symptoms.
The following surgical procedures were performed: tumor resection 41.66% (6 cases); ( Fig. 4 ), left splenopancreatectomy 25% (3 cases); spleen-preserving left pancreatectomy 16.66% (2 cases), pancreaticoduodenectomy 16.66% (2 cases) ( Fig. 5 ) and in one case (MEN I) tumor resection was associated with resection of a parathyroid adenoma.
The diagnosis was made by classical histopathological examination, special stains ( Fig. 6 ), electron microscopy in 3 cases, reveals pleomorphic granules, surrounded by a clear halo -typical appearance of insulin storage in beta cells (we detected in the same tumor gastrin secretory cells) ( Fig. 7 ) and confirmed by immunohistochemistry ( Fig. 8-10 ).
Postoperative complications after tumor resection were pancreatic fistula (2 cases) and pancreatic pseudocyst (1 case) and after pancreaticoduodenectomies delayed gastric emptying in one case.
About 10% of insulinomas are multiple and about 5% are associated with MEN 1 (6-8) (one case in our series -3,84%). In our case with MEN: a 28-year-old woman who neuropsihiatric symptoms was admitted with clinical and biological manifestations of insulinoma and hyperparathyroidism. Abdominal CT scan and Cervical ultrasound revealed pancreatic tumor and parathyroid adenoma. Pancreatic 
PNET -gastrinoma
The diagnosis of PNET -gastrinoma was based on Zollinger Ellison syndrome (ZES) is characterized by triad: gastric acid hypersecretion, jejunal peptic ulcer and PNET (12, 13) . In our series, the patients were presented with multiple complicated peptic ulcers and high gastrin levels: ultrasound and CT-scan identified the pancreatic tumor. For diagnosis very usefull are: endoscopic ultrasound with a sensitivity of 46% for duodenal gastrinomas, 75% for tumors with pancreatic localization and 57% for lymph node metastases; Octreoscan ® has a sensitivity of 65% for localized duodenal-pancreatic tumors, 20% for tumors located on the tail of the pancreas, and 71% for metastases and the combination of the two techniques increases the sensitivity to 94% (11) . The treatment of ZES has two objectives: control of gastric acid secretion and gastrinoma ablation. The patient diagnosed with ZES syndrome will receive gastric antisecretory treatment (proton pump inhibitors) until imaging investigations can locate the tumor and the tumor is removed. The doses will be adjusted so that the basal acid output to be below 10 mEq/h. In patients who underwent gastric resection the doses should ensure a basal acid output below 5 mEq/h. The already described principles of treatment should be also observed in case of sporadic forms, when pancreatic resections is indicated, and in case of metastases when an aggressive approach is recommended. Careful intraoperative exploration, supplemented by intraoperative ultrasound and perioperative echoendoscopy is mandatory, allowing the identification of the extra-pancreatic synchronous localization (gastric parietal, duodenal, biliary tract). The first two cases (48-and 62-year-old women, respectively) were admitted in emergency with peptic ulcers complications and different recurrent surgical procedures have been performed. In one case the postoperative course was unfavorable and then fatal due to complications of another peptic ulcers.
In another case, a 41-year-old woman with diffuse PNET located in the pancreatic tail we performed splenopancreatectomy with uneventful postoperative course. A 33-year-old woman was admitted in emergency for peritonitis caused by jejunal peptic ulcer perforation. We performed enterectomy; subsequently, ultrasound revealed a parathyroid adenoma and CT scan a pituitary adenoma (MEN I); angiography detected a possible 1.5 cm tumor in the pancreatic tail;
Reintervention was necessary (spleenpreserving left pancreatectomy). Postoperative course was unfavorable with upper GI hemorrhage and severe metabolic dysfunction and the patient died.
A 28-year-old man with history of various surgical interventions for recurrent peptic ulcers was admitted with hyperparathyroidism; imaging investigations detected a parathyroid adenoma and pituitary adenoma (MEN I) and possibly a pancreatic tail tumor. Resection of the tumor located in the pancreatic body ( Fig. 12 ) associated with total gastrectomy were performed. Postoperative course was uneventful and the patient is still alive. 
Nonfunctional PNET
Also operated were 5 patients with nonfunctional PNET -4 female and 1 male patients. Nonfunctional PNETs are pancreatic tumors with histological features of endocrine tumor but without hormone secretion, can produce polypeptides, but which are not functional and do not cause any symptoms. In our cases nonfunctional PNETs ranking third in frequency of PNETs, after insulinoma and gastrinoma, like in literature (6) . Nonfunctional PNETs are large (over 5 cm), solitary, over 60% have cephalic localization, and over 60% of cases are malignant. In 2 cases the tumors were located in the pancreatic tail (we performed splenopancreatectomy and spleen-preserving left pancreatectomy, respectively) and in the remaining 3 cases the tumors were located in the pancreatic head (pancreaticoduodenectomy and Beger's operation have been performed) (Fig. 13 ). The prognosis is better than for pancreatic adenocarcinomas, with a 5-year survival for malignant tumors exceeding 50%.
PNET -ACTHoma
A 27-year-old women was admitted with pain in the right abdominal quadrant, flush, amenorrhea, Cushing syndrome; ultrasound examination revealed multiple hypoechoic tumors of different sizes (30-45 mm) disseminated in the liver segments VI, VII and III. CT scan also confirmed the number and sites of liver tumors; no other tumors were found; the pancreas was described as "normal". Laparoscopic non-anatomic metastasectomyusing LigaSure (for histological exam) -and thermoablation of the other tumors were performed (Fig. 14) . Pathological exam revealed metastasis of one malignant endocrine tumor. Immunohisto-chemistry: positive staining for chromogranin, neuron specific enolase, and cytokeratins. After a few weeks, she was admitted to the Gastroenterology Institute for gastrointestinal bleeding. An upper endoscopy and video capsule endoscopy is used to diagnose multiple duodenal and jejunal hemorrhagic ulcers. Treatment consisted in octreotide, insulin, H+ blockers. The patient was then referred to the Endocrinology Clinic for further testing and were found a high cortisol levels, low potassium levels and high ACTH levels. Treatment with ketoconazole and metyrapone resulted in a decrease in plasma cortisol level. A new CT scan revealed a pancreatic tumor (3 x 2.5 x 1 cm), located in the pancreatic neck. PET scan revealed enlarged adrenal glands with intense marker uptake, a pancreatic tumor and multiple liver metastasis (Fig. 15 ). Indium 111 octreotride scan suggested 5 liver nodules, one pancreatic body nodule, and a right pelvic nodule ( Fig. 16 ). Following a new episode of gastrointestinal hemorrhage, upper endoscopy revealed acute esophagitis, esophageal stenosis and Barrett's esophagus. The patient underwent three more surgeries: bilateral ovariectomy, jejunostomy, and bilateral adrenalectomy for a better control of cortisol secretion. Microscopy revealed a metastasis of endocrine tumor in resected right ovary and hyperplasia of adrenal glands. Immunehistochemistry: intensly positive chromogranin, synaptophysin, Ki 67 89%. A vertebral metastasis causing paraplegia complicated the course and she died 18 months after first hospital admission.
ACTH-secreting PNETs are very rare, so far less than 100 ACTHomas have been reported in the literature. Ectopic ACTH syndrome (EAS) occurs in about 5-10% of all patients with ACTH-dependent hypercortisolism (14) . Most ACTHomas are malignant, at the time of diagnosis 80-90% being metastatic. Clinically they are characterized by the occurrence of a severe Cushing's syndrome: central obesity, hirsutism, telangiectasia, stretch marks, and hyperhidrosis. Metastases, who are present at the time of diagnosis, are most commonly hepatic, but quite frequently they are also detected in the ovary, fact confirmed by our case and aggressive surgical cytoreduction, with resection/ destruction of primary tumor and hepatic and extrahepatic metastases is the only option to control the symptoms. Adrenalectomy is also indicated to control cortisolemia (15) . As to the drug treatment, ketoconazole and somatostatin analogues appear to be effective in controlling hypercortisolemia (16) .
Conclusions
Pancreatic endocrine tumors (PET) are rare tumors but their incidence is increasing. They have a relatively heterogeneous morphology and their management is always challenging. Immunohistochemistry -mandatory for: confirmation (most cases were highly/ moderately positive for chromogranin), assessment of proliferation and biological behavior, thus facilitating the use of specific therapy -Sandostatin.
For all PNETs, it is necessary to recognize the clinical signs of secreting tumors and to plan the laboratory investigations.
In insulinomas, less aggressive pancreatic resection is preferred to tumor resection, which has a higher postoperative morbidity rate. Gastrinomas and ACTHomas are aggressive tumors with a poor prognosis.
Tumor resection, absence of liver and lymph node metastases, and the presence of MEN 1 syndrome are associated with a better survival rate.
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